What is Bifidobacterium bifidum BGN4 and how is it different from other Bifidobacterium strains?

Bifidobacterium bifidum BGN4 is a specific, characterized probiotic strain with a unique genetic identity distinct from other B. bifidum strains. Its documented ability to suppress IFN-γ and MCP-1 cytokines while simultaneously upregulating antioxidant enzymes (SOD, GSH-Px, CAT) makes it of particular research interest for inflammatory bowel conditions, though strain-specific human trials remain limited.

What does Bifidobacterium bifidum BGN4 do for inflammatory bowel disease?

In mouse models of colitis, BGN4 supplementation reduced CD4+ T cell infiltration into the colon and lowered levels of pro-inflammatory cytokines IFN-γ and MCP-1, which are key drivers of IBD-related mucosal damage. It also improved measurable colon length—a marker of inflammation severity in animal models—though these findings have not yet been replicated in controlled human clinical trials.

What is the recommended dosage of Bifidobacterium bifidum BGN4?

No established clinical dosage has been confirmed for BGN4 specifically in human trials. General probiotic research for Bifidobacterium strains typically uses doses ranging from 1 billion to 10 billion CFU (colony-forming units) per day, and BGN4 commercial preparations often fall within this range. Always follow manufacturer guidelines and consult a healthcare provider for personalized dosing advice.

Is Bifidobacterium bifidum BGN4 safe to take with antibiotics?

Antibiotics, particularly broad-spectrum agents like amoxicillin or ciprofloxacin, can significantly reduce the viability of BGN4 and other probiotic strains by killing beneficial bacteria. It is generally recommended to take probiotic supplements at least 2 hours before or after an antibiotic dose to minimize this interaction, and to resume regular probiotic use after completing the antibiotic course to help restore gut microbiota balance.

How does Bifidobacterium bifidum BGN4 affect antioxidant enzymes in the gut?

BGN4 has been shown in preclinical studies to upregulate three critical antioxidant enzymes in colon tissue: superoxide dismutase (SOD), which dismutates the superoxide radical; glutathione peroxidase (GSH-Px), which reduces hydrogen peroxide using glutathione; and catalase (CAT), which decomposes hydrogen peroxide into water and oxygen. This coordinated enzyme upregulation helps neutralize reactive oxygen species (ROS) generated during intestinal inflammation, thereby reducing oxidative damage to the colonic epithelium.

What is the current evidence quality for Bifidobacterium bifidum BGN4 in human clinical trials?

Most evidence for Bifidobacterium bifidum BGN4 comes from animal models and in vitro studies, with limited human clinical trial data currently available. While preclinical research shows promise for IBD symptoms and gut barrier function, larger randomized controlled trials in humans are needed to confirm efficacy and establish clinical significance. Current human studies are insufficient to make definitive claims about therapeutic effectiveness in patients.

Who should consider taking Bifidobacterium bifidum BGN4 supplementation?

Bifidobacterium bifidum BGN4 may be beneficial for individuals with inflammatory bowel disease or compromised gut barrier function, particularly those seeking to support intestinal health through probiotics. However, it is best suited for adults, as safety and efficacy in children and pregnant women have not been well-established. Consultation with a healthcare provider is recommended before starting supplementation, especially for those with severe IBD or immunocompromised conditions.

How does Bifidobacterium bifidum BGN4 compare to other bifidobacterial strains for gut barrier support?

Bifidobacterium bifidum BGN4 specifically shows promise for enhancing tight junction gene expression based on preliminary research, which may distinguish it from other Bifidobacterium species with different mechanisms of action. Direct comparative clinical studies between BGN4 and other bifidobacterial strains in humans are limited, making definitive effectiveness rankings difficult. The strain-specific nature of probiotics means that BGN4's benefits may not generalize to other Bifidobacterium strains.

Bifidobacterium bifidum BGN4

Bifidobacterium bifidum BGN4 is a specific probiotic strain that modulates gut immunity by suppressing pro-inflammatory cytokines such as IFN-γ and MCP-1 while reducing CD4+ T cell infiltration in intestinal tissue. Its primary mechanism involves enhancing antioxidant enzyme activity—including superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and catalase (CAT)—to protect the colonic epithelium from oxidative damage.

Category: Fermented/Probiotic Evidence: 2/10 Tier: Preliminary (in-vitro/animal)

Bifidobacterium bifidum BGN4 — Hermetica Encyclopedia

Origin & History

Bifidobacterium bifidum BGN4 is a specific probiotic strain isolated from human gut microbiome and used in nutraceutical products and dairy starters since 2000. It is cultivated as live bacterial cells, recombinant variants (e.g., BGN4-SK expressing superoxide dismutase), or lysed/paraprobiotic forms via enzymatic/physical processing.

Historical & Cultural Context

No historical or traditional medicine use is documented for Bifidobacterium bifidum BGN4. It is a modern probiotic strain developed for commercial nutraceuticals and dairy products since 2000, without ties to traditional medicine systems.

Health Benefits

• May reduce inflammatory bowel disease symptoms by decreasing CD4+ T cell infiltration and suppressing inflammatory cytokines (IFN-γ/MCP-1) - evidence from mouse models only
• Could protect against colitis by improving colon length and boosting antioxidant enzymes (SOD, GSH-Px, CAT) - preliminary animal evidence
• May support gut barrier function through enhanced tight junction gene expression - shown in DSS-induced colitis mouse models
• Potentially reduces inflammatory markers (TNF-α, IL-8, IL-6) in immune cells - demonstrated in cell culture studies
• Possible reduction in abdominal pain and defecation discomfort - limited evidence from one mixed probiotic human trial

How It Works

BGN4 downregulates the Th1-driven immune response by reducing CD4+ T cell infiltration into colonic tissue and suppressing the pro-inflammatory cytokines interferon-gamma (IFN-γ) and monocyte chemoattractant protein-1 (MCP-1), thereby limiting immune-mediated mucosal damage. Simultaneously, the strain upregulates key antioxidant enzymes—superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and catalase (CAT)—which neutralize reactive oxygen species (ROS) generated during intestinal inflammation. These combined immunomodulatory and antioxidant actions help preserve colon length and epithelial integrity under inflammatory conditions.

Scientific Research

Evidence for BGN4 is limited to preclinical studies including mouse models of IBD (PMID: 17218154) and colitis (PMIDs: 35148194, 35672695), plus in vitro cell culture experiments. No human randomized controlled trials specifically testing BGN4 alone have been identified, with only one referenced mixed probiotic study (n=70) showing digestive benefits.

Clinical Summary

Current evidence for Bifidobacterium bifidum BGN4 is largely derived from preclinical mouse models of colitis, where oral administration improved colon length, reduced inflammatory cytokine expression, and enhanced antioxidant enzyme activity. No large-scale randomized controlled trials in humans have been published specifically for the BGN4 strain as of the latest available data. Some broader research on Bifidobacterium bifidum species supports gut health and immune benefits in humans, but strain-specific human data for BGN4 remains limited. Consumers should view existing findings as preliminary and hypothesis-generating rather than conclusive clinical evidence.

Nutritional Profile

Bifidobacterium bifidum BGN4 is a probiotic bacterial strain, not a conventional food ingredient, so macronutrient and micronutrient content is not applicable in traditional dietary terms. As a lyophilized or encapsulated probiotic preparation, the active component is viable bacterial cells, typically delivered at concentrations of 1×10⁸ to 1×10¹⁰ CFU (colony-forming units) per dose depending on the commercial formulation. The bacterial cells themselves contain: protein (~50-60% of dry cell mass, primarily structural and enzymatic proteins including surface-layer proteins and adhesins); lipids (~10-20% of dry mass, predominantly phospholipids and glycolipids forming the cell membrane); carbohydrates (~10-20% of dry mass, including exopolysaccharides and cell wall peptidoglycan/teichoic acids). Bioactive compounds of functional relevance include: exopolysaccharides (EPS) produced by BGN4, which have demonstrated immunomodulatory properties; short-chain fatty acids (SCFAs such as acetate and lactate) generated as fermentation metabolites in the gut, though concentrations are gut-environment dependent and not fixed in the supplement itself; surface-layer proteins that mediate host cell adhesion and immune signaling. The strain produces β-galactosidase enzyme activity, supporting lactose metabolism. Bioavailability of the bacterial cells depends heavily on the delivery matrix — enteric-coated or microencapsulated forms demonstrate superior gastric acid survival (>70% viability at gastric pH 2.0 for 2 hours in optimized formulations) compared to unprotected forms. No significant direct contribution of conventional vitamins or dietary minerals from the strain itself at typical supplemental doses.

Preparation & Dosage

Clinically studied dosages are not established for humans. Mouse studies used 0.3% w/w BGN4 in diet for 4 weeks. No standardized CFU counts or human dosage ranges are specified in available research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other Bifidobacterium strains, Lactobacillus species, Prebiotics (FOS/GOS), Glutamine, Curcumin

Safety & Interactions

Bifidobacterium bifidum BGN4 is generally considered safe for healthy adults, consistent with the well-established safety profile of Bifidobacterium species classified as GRAS (Generally Recognized as Safe) by the FDA. Immunocompromised individuals, critically ill patients, and those with central venous catheters should use caution with any probiotic, as rare cases of bacteremia have been reported with Bifidobacterium species in vulnerable populations. Concurrent use with broad-spectrum antibiotics may reduce BGN4 viability and efficacy; spacing probiotic intake at least 2 hours from antibiotic doses is commonly recommended. Pregnancy and breastfeeding safety data specific to BGN4 is insufficient, so consultation with a healthcare provider is advised before use.